Journal
CHEMISTRY & BIODIVERSITY
Volume 5, Issue 10, Pages 2140-2155Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cbdv.200890195
Keywords
-
Funding
- FFG-Austrian Research Promotion Agency [811591]
- Austrian Council for Research and Technology Development [IS526001]
- FWF - Austrian Science Fund [P16186-NO3, P18123-N11, P16192-NO3]
- C.G.H. Schrodinger Fellowship [J2613-N19]
- COST [D39]
Ask authors/readers for more resources
The promising drug candidate indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) is the second Ru-based anticancer agent to enter clinical trials. In this review, which is an update of a paper from 2006 (Hartinger al., J. Inorg. Biochem. 2006,100, 891-904), the experimental evidence for the proposed mode of action of this coordination compound is discussed, including transport into the cell via the transferrin cycle and activation by reduction. The results of the early clinical development of KP1019 are summarized in which five out of six evaluated patients experienced disease stabilization with no severe side effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available